218 related articles for article (PubMed ID: 31454890)
21. The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats.
Hsu SJ; Wang SS; Huo TI; Lee FY; Huang HC; Chang CC; Hsin IF; Ho HL; Lin HC; Lee SD
J Pharmacol Exp Ther; 2015 Oct; 355(1):117-24. PubMed ID: 26260462
[TBL] [Abstract][Full Text] [Related]
22. Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution.
Hsu SJ; Tsai MH; Chang CC; Hsieh YH; Huang HC; Lee FY; Chuang CL; Hou MC; Lee SD
Clin Sci (Lond); 2018 Mar; 132(6):669-683. PubMed ID: 29449343
[TBL] [Abstract][Full Text] [Related]
23. Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats.
Pun CK; Chang CC; Chuang CL; Huang HC; Hsu SJ; Huang YH; Hou MC; Lee FY
J Chin Med Assoc; 2023 Sep; 86(9):786-794. PubMed ID: 37462441
[TBL] [Abstract][Full Text] [Related]
24. Lycopene treatment improves intrahepatic fibrosis and attenuates pathological angiogenesis in biliary cirrhotic rats.
Huang HC; Hsu SJ; Chang CC; Kao YC; Chuang CL; Hou MC; Lee FY
J Chin Med Assoc; 2022 Apr; 85(4):414-420. PubMed ID: 35120355
[TBL] [Abstract][Full Text] [Related]
25. Effects of raloxifene on portal hypertension and hepatic encephalopathy in cirrhotic rats.
Chang CC; Lee WS; Chuang CL; Hsin IF; Hsu SJ; Chang T; Huang HC; Lee FY; Lee SD
Eur J Pharmacol; 2017 May; 802():36-43. PubMed ID: 28238769
[TBL] [Abstract][Full Text] [Related]
26. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
Tsai HC; Li TH; Huang CC; Huang SF; Liu RS; Yang YY; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
Am J Pathol; 2018 Jul; 188(7):1608-1624. PubMed ID: 29929914
[TBL] [Abstract][Full Text] [Related]
27. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.
Angermayr B; Fernandez M; Mejias M; Gracia-Sancho J; Garcia-Pagan JC; Bosch J
Gut; 2007 Apr; 56(4):560-4. PubMed ID: 16854998
[TBL] [Abstract][Full Text] [Related]
28. Ascorbate lacks significant influence in rats with bile duct ligation-induced liver injury.
Ho HL; Huo TI; Chang T; Lee WS; Hsin IF; Lee FY; Huang HC; Hou MC; Lee SD
J Chin Med Assoc; 2017 Sep; 80(9):539-550. PubMed ID: 28684188
[TBL] [Abstract][Full Text] [Related]
29. NADPH oxidase 1/4 inhibition attenuates the portal hypertensive syndrome via modulation of mesenteric angiogenesis and arterial hyporeactivity in rats.
Deng W; Duan M; Qian B; Zhu Y; Lin J; Zheng L; Zhang C; Qi X; Luo M
Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):255-265. PubMed ID: 30413372
[TBL] [Abstract][Full Text] [Related]
30. Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats.
Tung HC; Hsu SJ; Tsai MH; Lin TY; Hsin IF; Huo TI; Lee FY; Huang HC; Ho HL; Lin HC; Lee SD
Clin Sci (Lond); 2017 Jan; 131(1):69-86. PubMed ID: 27803296
[TBL] [Abstract][Full Text] [Related]
31. Portosystemic collaterals are not prerequisites for the development of hepatic encephalopathy in cirrhotic rats.
Hsin IF; Wang SS; Huang HC; Lee FY; Chan CY; Chang CC; Hsu CY; Lin HC; Lee SD
J Chin Med Assoc; 2012 Jan; 75(1):3-9. PubMed ID: 22240529
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Reiberger T; Angermayr B; Schwabl P; Rohr-Udilova N; Mitterhauser M; Gangl A; Peck-Radosavljevic M
J Hepatol; 2009 Nov; 51(5):865-73. PubMed ID: 19726100
[TBL] [Abstract][Full Text] [Related]
33. Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.
Wang D; Wang Q; Yin J; Dong R; Wang Q; Du X; Lu J
J Gastroenterol Hepatol; 2016 May; 31(5):1037-44. PubMed ID: 26487394
[TBL] [Abstract][Full Text] [Related]
34. Concomitant inhibition of oxidative stress and angiogenesis by chronic hydrogen-rich saline and N-acetylcysteine treatments improves systemic, splanchnic and hepatic hemodynamics of cirrhotic rats.
Lee PC; Yang YY; Huang CS; Hsieh SL; Lee KC; Hsieh YC; Lee TY; Lin HC
Hepatol Res; 2015 May; 45(5):578-88. PubMed ID: 24961937
[TBL] [Abstract][Full Text] [Related]
35. Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.
Gao JH; Wen SL; Yang WJ; Lu YY; Tong H; Huang ZY; Liu ZX; Tang CW
PLoS One; 2013; 8(7):e69309. PubMed ID: 23922700
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats.
Mejias M; Coch L; Berzigotti A; Garcia-Pras E; Gallego J; Bosch J; Fernandez M
Gut; 2015 Apr; 64(4):657-66. PubMed ID: 24848263
[TBL] [Abstract][Full Text] [Related]
37. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study.
Geerts AM; De Vriese AS; Vanheule E; Van Vlierberghe H; Mortier S; Cheung KJ; Demetter P; Lameire N; De Vos M; Colle I
Liver Int; 2006 Sep; 26(7):889-98. PubMed ID: 16911473
[TBL] [Abstract][Full Text] [Related]
38. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of nitric oxide synthase in hyperdynamic circulation of rats with early or late cirrhosis secondary to common bile duct ligation.
Kato Y; Katsuta Y; Zhang XJ; Ohsuga M; Akimoto T; Miyamoto A; Komeichi H; Shimizu S; Mizuno K
J Nippon Med Sch; 2011; 78(3):146-55. PubMed ID: 21720088
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives.
Garbuzenko DV; Arefyev NO; Kazachkov EL
World J Gastroenterol; 2018 Sep; 24(33):3738-3748. PubMed ID: 30197479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
